Routy et al. demonstrated, in non-small-cell lung cancer (NSCLC) patients receiving PD-1/PD-L1 monoclonal antibody treatment, a significant enrichment of Akkermansia muciniphila in the stools of responders compared with non-responders [38]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.